Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
218
-
Total 13F shares, excl. options
-
107M
-
Shares change
-
-2.44M
-
Total reported value, excl. options
-
$2.4B
-
Value change
-
-$56.5M
-
Put/Call ratio
-
0.69
-
Number of buys
-
106
-
Number of sells
-
-94
-
Price
-
$22.41
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q3 2022
255 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q3 2022.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 218 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 107M shares
of 114M outstanding shares and own 93.94% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (13M shares), ARK Investment Management LLC (11.7M shares), Capital World Investors (8.23M shares), BlackRock Inc. (7.92M shares), VANGUARD GROUP INC (7.81M shares), STATE STREET CORP (4.38M shares), Bellevue Group AG (3.75M shares), JOHNSON & JOHNSON (3.38M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.14M shares), and Artal Group S.A. (2.6M shares).
This table shows the top 218 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.